newsfilter
← Latest News
GlobeNewswire·

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for AAV in Europe Reported